This medicine is authorised for use in the European Union.


Kymriah is a medicine for treating the following types of blood cancer:

• B-cell acute lymphoblastic leukaemia (ALL), in children and young adults up to 25 years of age whose cancer did not respond to previous treatment, has come back two or more times, or has come back after a transplant of stem cells;

• Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in adults whose cancer has come back or did not respond after two or more previous treatments.

Kymriah is a type of advanced therapy medicine called a ‘gene therapy product’. This is a type of medicine that works by delivering genes into the body.

The blood cancers that Kymriah is used to treat are rare, and Kymriah was designated an ‘orphan medicine’ (a medicine used in rare diseases) for B-cell ALL on 29 April 2014, DLBCL on 14 October 2016 and FL on 19 July 2021.

Kymriah contains the active substance tisagenlecleucel (consisting of genetically modified white blood cells).

This EPAR was last updated on 10/05/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.


This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Vista Building
Elm Park, Merrion Road
Dublin 4

Product information

26/04/2023 Kymriah - EMEA/H/C/004090 - R/0068

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other antineoplastic agents

Therapeutic indication

Kymriah is indicated for the treatment of:

• Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse.

• Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.

• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
7 ratings
3 ratings
1 rating
4 ratings